As part of our ongoing commitment to supporting the evolving needs of the biopharmaceutical industry, Avance Biosciences is pleased to announce the addition of our LC-MS/MS services, enabling highly sensitive and specific bioanalytical testing.
LC-MS/MS is a powerful analytical tool for the quantitative and qualitative analysis of small molecules, peptides, oligonucleotides, and biomarkers, playing a critical role in drug substance characterization and ensuring the safety and efficacy of biologics. This new offering builds on our recent laboratory expansion and further strengthens our position as a trusted CRO partner across the drug development lifecycle.
Utilizing state-of-the-art SCIEX Triple Quad™ and TripleTOF™ LC-MS platforms, our services support a wide range of applications including pharmacokinetic (PK) and pharmacodynamic (PD) studies, metabolite identification, targeted proteomics, and impurity profiling.
Our LC-MS/MS capabilities complement an extensive suite of existing technologies, spanning qPCR, NGS, ddPCR, cell-based potency assays, and immunoassays such as ELISA and MSD, providing integrated solutions for the development of mAbs, ADCs, gene therapies, mRNA therapeutics, oligonucleotide drugs, and other modalities.
Avance remains dedicated to expanding our capabilities and investing in advanced technologies that support our clients’ success from early discovery through commercialization.
To learn more about our LC-MS/MS services, visit: https://www.avancebio.com/tecchnology/genomic-services/lc-ms-ms-services/